Tests NEO100 in people with high-grade meningioma that is left over, growing, or returning
Tests the drug NEO100 in people with a serious type of brain tumor.
Key facts
- Who runs it
- Neonc Technologies, Inc.
- Where
- Boston, Dallas, Los Angeles, San Francisco, and Santa Monica, United StatesSee the 5 sites
- Trial code
- Registry title
- NEO100 and High-Grade Meningioma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 1 Jul 2022
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Treatments tested
- NEO100
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with grade II or III meningioma that has remained after surgery, grown, or come back after surgery and radiation.
- Age
- 12 years and older
- Sex
- All sexes can join
- Disease stage
- Grade II or III (WHO) meningioma that is residual, progressive or recurrent after surgery and radiation. Metastatic meningiomas are allowed. Measurable disease on MRI, at least 10mm in both dimensions.
- Earlier treatment
- Must have had surgery and radiation therapy. No limit on the number of earlier treatments. No chemotherapy or other trial drugs within 14 days of starting. Must be on a stable or decreasing steroid dose for at least 5 days. No earlier perillyl alcohol.
Main reasons for not taking part
- Cancer other than high-grade meningioma in the last five years (except skin basal or squamous cell carcinoma)
- Disease mainly in the brainstem or spinal cord
- Leptomeningeal involvement of the tumor
- Pregnant or breastfeeding
- Earlier treatment with perillyl alcohol or an allergic reaction to it
The registry criteria, word for word
Show all 40 criteriaShow less
Who can take part
- Patient must:
- Have histologically confirmed WHO Grade II or III meningioma that is residual, progressive or recurrent following at least minimally safe resection and radiation therapy. Metastatic meningiomas are allowed; Residual disease is defined as residual measurable disease (without a requirement for progression). Residual measurable disease is defined by bidimensionally measurable lesions with clearly defined margins by MRI scan(s) with a minimum diameter of 10mm in both dimensions; Progressive disease is defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area). The change must occur between scans separated by no more than 24 months; Recurrent disease is defined as new evidence of measurable disease following complete resection (10mm in both dimensions)
- Be on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent
- Participants must have failed maximal safe resection and radiation therapy
- There is no limit on the number of prior surgeries, radiation therapy, radiosurgery treatments or systemically administered therapeutic agents, however, these treatment(s) must comply with the following:; There is no limit on the number of prior therapies; Prior medical therapy is allowed but is not required; No chemotherapy, other investigational agents within 14 days of study treatment; For prior systemic agents, participants must be at least 4 weeks (or 5 half-lives, whichever is shorter) from other prior cytotoxic chemotherapy (6 weeks from nitrosoureas/alkylating agents) or biologic therapies; No other concurrent receipt of investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study; Patients may have been treated with standard external beam radiation or radiosurgery in any combination; however an interval of ≥12 weeks (84 days) must have elapsed from the completion of the radiation therapy to the initiation of study therapy unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line). In addition, there must be subsequent evidence of tumor progression after completion of radiation therapy; An interval of ≥ 28 days and full recovery (no ongoing safety issues) from surgical resection is required; Meningiomas that have resulted from prior radiation therapy are allowed; There must be an interval of ≥ 7 days from stereotactic biopsy; and
- Participants must have recovered to grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include, but are not limited to alopecia, laboratory values listed per inclusion criteria and lymphopenia)
- Patient must be ≥ 12 years of age
- Patient must have an ECOG performance status of 0-2 or KPS ≥ 60
- Patient must have an expected survival of at least three months
- Patient must be willing to provide blood sample for pharmacokinetic study (to assess proper administration of NEO100)
- Patient must have adequate organ and marrow function as defined below:
- White blood cell (WBC) ≥2000/microliter
- Absolute neutrophil count (ANC) ≥ 1,500/microliter
- Platelets ≥ 100,000/microliter
- Hemoglobin ≥9 gm/dl
- AST (SGOT)/ALT (SPGT) ≤ 2.5 × laboratory upper limit of normal (ULN)
- Serum creatinine ≤ 1.5 x laboratory upper limit of normal (ULN) or
- Creatinine clearance (meas or calc) ≥60mL/min for participants with creatinine levels >1.5x laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 1.5 x laboratory upper limit of normal (ULN) except participants with Gilbert's Syndrome who can have a total serum bilirubin of <5 x laboratory upper limit of normal (ULN)
- MRI (or CT if MRI contraindicated) within 14 days prior to start of study drug. Corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the screening scan and the start of treatment, a new baseline scan is required
- Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first administration of study drug, for the duration of study participation, and for 90 days following completion of therapy. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- A female of child-bearing potential is any woman (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:; Has not undergone a hysterectomy or bilateral oophorectomy; or; Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
- A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to initiating study drug
- A serum pregnancy test will be repeated immediately if pregnancy is suspected
- Women must not be breastfeeding
- Patient must have the ability to understand, and the willingness comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study as confirmed by signing a written informed consent document
Who cannot take part
- Patients who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days (or 5 half-lives, whichever is shorter) of study treatment
- Patient has completed chemo-radiation within the last 84 days prior to the first administration of study drug, unless new contrast enhancement is outside of radiation field, or there is tissue proven recurrence or progression
- Patient has had surgery within seven days prior to the date of informed consent
- Patient has had cytotoxic chemotherapy within 4 weeks (or 5 half-lives, whichever is shorter), nitrosoureas/alkylating agents within 6 weeks or biologic therapies
- Prior treatment with interstitial brachytherapy within 6 months of start of study therapy
- Current or planned participation in a clinical trial of an investigational agent or using an investigational medical device
- Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy
- Patient has had prior treatment with perillyl alcohol
- Patient has a history of new diagnosis or treatment of cancer other than high-grade meningioma within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin
- The patient's disease is primarily localized to the brainstem or spinal cord
- Patient has a history of allergic reactions attributed to perillyl alcohol
- Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patient must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
- Leptomeningeal involvement of the patient's tumor
Where in United States
- Tufts Medical CenterBoston, United StatesContact: Christian LawlorTaking people
- Baylor Scott and WhiteDallas, United StatesContact: Tarah SatterfieldTaking people
- University of Southern CaliforniaLos Angeles, United StatesContact: Sandy TranTaking people
- Sutter Health Research InstituteSan Francisco, United StatesContact: Andrea DavilaTaking people
- Saint John Cancer InstituteSanta Monica, United StatesContact: Aleena FloresTaking people
About the trial
What the trial wants to find out
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
The group in the trial
- Patients with high-grade meningiomaTreatment being tested
30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
Treatment: NEO100
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma
- Plain-language title
- Tests NEO100 in people with high-grade meningioma that is left over, growing, or returningGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 September 2026